Edition:
United Kingdom

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,515.50GBp
4:53pm BST
Change (% chg)

20.00 (+0.44%)
Prev Close
4,495.50
Open
4,504.50
Day's High
4,545.00
Day's Low
4,504.50
Volume
1,816,276
Avg. Vol
2,142,614
52-wk High
4,576.00
52-wk Low
2,940.50

Latest Key Developments (Source: Significant Developments)

Shire Says Receives Approval Of Firazyr In Japan
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Shire PLC ::SHIRE RECEIVES APPROVAL OF FIRAZYR® (ICATIBANT INJECTION) FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA (HAE) ATTACKS IN JAPAN.SHIRE PLC - STUDY SHOWED THAT FIRAZYR WAS WELL TOLERATED AND DEMONSTRATED SYMPTOM RELIEF DURING AN ACUTE HAE ATTACK THROUGH A SINGLE INJECTION.  Full Article

Takeda Is Said To Weigh Sale Of Shire Eye Care Drug To Cut Debt - Bloomberg
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - :TAKEDA IS SAID TO WEIGH SALE OF SHIRE EYE CARE DRUG TO CUT DEBT - BLOOMBERG, CITING SOURCES.  Full Article

Shire Announces Tender Offer For Up To $2.25 Bln Outstanding Notes
Friday, 24 Aug 2018 

Aug 24 (Reuters) - Shire PLC ::ANNOUNCES CASH TENDER OFFERS FOR UP TO $2,250,000,000 OUTSTANDING PRINCIPAL AMOUNT OF NOTES.COMMENCED CASH TENDER OFFERS TO PURCHASE UP TO $2.25 BILLION OF BAXALTA'S OUTSTANDING 2.875% SENIOR NOTES DUE 2020, AMONG OTHERS.  Full Article

FDA approves potential blockbuster drug from Shire for rare swelling disorder
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - U.S. Food And Drug Administration: :U.S. FDA - APPROVED TAKHZYRO, FIRST MONOCLONAL ANTIBODY APPROVED IN U.S. TO TREAT PATIENTS 12 YRS & OLDER WITH TYPES I AND II HEREDITARY ANGIOEDEMA.  Full Article

Takeda Pharmaceutical Announces Statement Regarding US FTC Clearance
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Takeda Pharmaceutical Company Ltd <4502.T>::STATEMENT REGARDING US FTC CLEARANCE.TAKEDA RECEIVES CLEARANCE FROM UNITED STATES FEDERAL TRADE COMMISSION FOR PROPOSED ACQUISITION OF SHIRE PLC.  Full Article

Takeda Pharm CEO Weber Says Neuroscience Will Continue To Be A Core Area
Tuesday, 8 May 2018 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T> Chief Executive Officer Christophe Weber::NEUROSCIENCE WILL CONTINUE TO BE A CORE AREA.JOBS COULD BE IMPACTED.  Full Article

GSK New R&D Head Barron Says Work To Do To Translate DPU Research Into Drugs
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Glaxosmithkline ::NEW RESEARCH AND DEVELOPMENT HEAD BARRON SAYS WORK TO DO TO TRANSLATE RESEARCH AT DPU UNITS INTO DRUGS.  Full Article

GSK Expecting Shingrix Sales For Year To Be Above 400 Million Stg
Wednesday, 25 Apr 2018 

April 25 (Reuters) - GlaxoSmithKline ::CFO SAYS EXPECTING SHINGRIX SALES FOR YEAR TO BE AT THE SAME RATE AS IN Q1, OR 400 MILLION STG+ FOR 2018.  Full Article

Takeda Says Notes Statement By Shire Regarding Revised Proposal, Deadline Extension
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd <4502.T>::SAYS NOTES STATEMENT BY SHIRE PLC REGARDING REVISED PROPOSAL AND EXTENSION OF PUSU DEADLINE TO MAY 8, 2018.SAYS INTENDS TO MAINTAIN ITS WELL-ESTABLISHED DIVIDEND POLICY AND INVESTMENT GRADE CREDIT RATING.  Full Article

Shire announces Takeda's revised proposal of about 49 pounds per share
Wednesday, 25 Apr 2018 

April 24 (Reuters) - Shire Plc ::SHIRE ANNOUNCES REVISED PROPOSAL AND EXTENSION OF PUSU DEADLINE TO 8 MAY 2018.INDICATED TO TAKEDA WOULD BE WILLING TO RECOMMEND REVISED PROPOSAL TO SHAREHOLDERS SUBJECT TO SATISFACTORY RESOLUTION OF OTHER TERMS OF POSSIBLE OFFER.SATISFACTORY RESOLUTION OF OTHER TERMS OF POSSIBLE OFFER, INCLUDE COMPLETION OF RECIPROCAL DUE DILIGENCE BY SHIRE ON TAKEDA.REVISED PROPOSAL COMPRISES 0.839 NEW TAKEDA SHARES AND US$30.33 IN CASH FOR EACH SHIRE ORDINARY SHARE.REVISED PROPOSAL IMPLIES AN EQUIVALENT VALUE OF APPROXIMATELY £49 PER SHIRE ORDINARY SHARE.REVISED PROPOSAL COMPRISING OF £27.26 IN NEW TAKEDA SHARES; AND £21.75 IN CASH.REVISED PROPOSAL IS EQUIVALENT TO A VALUE OF APPROXIMATELY £46 BILLION FOR ENTIRE ISSUED AND TO BE ISSUED SHARE CAPITAL OF COMPANY.CO SHAREHOLDERS WOULD BE ENTITLED TO ANY DIVIDENDS ANNOUNCED BY SHIRE IN ORDINARY COURSE PRIOR TO COMPLETION OF POSSIBLE TRANSACTION.ON DEAL COMPLETION, SHIRE SHAREHOLDERS WOULD OWN APPROXIMATELY 50 PER CENT.OF THE ENLARGED TAKEDA AND THE NEW TAKEDA SHARES WILL BE LISTED IN JAPAN AND IN US THROUGH AN ADR PROGRAM.  Full Article

Bayer hemophilia treatment wins thumbs-up from EU panel

Sept 21 Bayer AG's long-acting treatment for hemophilia A has won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily.